Coagulopathy-Directed Therapy in Hemorrhage | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Coagulopathy-Directed Therapy in Massive Hemorrhage [ Medical Education ](https://mdster.com/blog?category=medical-education) Coagulopathy-Directed Therapy in Massive Hemorrhage ===================================================== How to think about fibrinogen, platelets, and viscoelastic data when the field is flooding and time is disappearing [ MDster Editorial Team ](https://mdster.com/about) · Apr 10, 2026 · 4 min read · 117 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Anesthesiology ](https://mdster.com/blog?tag=anesthesiology) [ Anesthesiology Boards ](https://mdster.com/blog?tag=anesthesiology-boards) [ Transfusion Medicine ](https://mdster.com/blog?tag=transfusion-medicine) [ Massive Hemorrhage ](https://mdster.com/blog?tag=massive-hemorrhage) [ Coagulopathy ](https://mdster.com/blog?tag=coagulopathy) [ Viscoelastic Testing ](https://mdster.com/blog?tag=viscoelastic-testing) ![Coagulopathy-Directed Therapy in Massive Hemorrhage](https://mdster.com/storage/blog/images/coagulopathy-directed-therapy-in-massive-hemorrhage.jpg) Share this article Share this post On this page 1. [ Start with clot mechanics ](#start-with-clot-mechanics) 2. [ Fibrinogen replacement concept ](#fibrinogen-replacement-concept) 3. [ Platelet thresholds concept ](#platelet-thresholds-concept) 4. [ Viscoelastic-guided therapy concept ](#viscoelastic-guided-therapy-concept) 5. [ Clinical correlations ](#clinical-correlations) 6. [ Key Takeaways ](#key-takeaways) 7. [ Frequently Asked Questions ](#blog-faqs) 8. [ References ](#references-heading) On this page 1. [ Start with clot mechanics ](#start-with-clot-mechanics) 2. [ Fibrinogen replacement concept ](#fibrinogen-replacement-concept) 3. [ Platelet thresholds concept ](#platelet-thresholds-concept) 4. [ Viscoelastic-guided therapy concept ](#viscoelastic-guided-therapy-concept) 5. [ Clinical correlations ](#clinical-correlations) 6. [ Key Takeaways ](#key-takeaways) 7. [ Frequently Asked Questions ](#blog-faqs) 8. [ References ](#references-heading) The oral-board version of this case is always the same: blood loss is rising, the field has turned into diffuse ooze, and someone asks for more plasma because the INR is 1.6. That is how coagulopathy becomes a logistics problem instead of a thinking problem. In massive hemorrhage, lead by phenotype. Decide whether the patient lacks fibrinogen, platelets, thrombin generation, or all three, and replace what is actually missing before dilution, hypothermia, acidosis, and time finish the job. Modern trauma guidance favors goal-directed resuscitation, and standard coagulation labs are often too slow for the pace of real bleeding. [\[1\]](#cite-1 "Reference [1]") Start with clot mechanics ------------------------- Picture the clot, not the lab sheet. Fibrinogen is the substrate that becomes fibrin and also supports platelet aggregation, so when fibrinogen falls the clot becomes weak early. That is why fibrinogen is often the first coagulation factor to reach critical levels during major bleeding. Platelets are the second half of the story: count matters, but function matters just as much after CPB, hypothermia, acidosis, antiplatelet therapy, and massive transfusion. If you only chase PT/INR, you miss the mechanical reason the patient is still oozing. [\[2\]](#cite-2 "Reference [2]") > **Clinical Pearl:** Plasma is a poor fibrinogen drug. If the clot is weak because fibrinogen is low, go straight to cryoprecipitate or fibrinogen concentrate rather than giving liters of plasma and hoping the number moves. Guidelines note that plasma is inefficient for raising fibrinogen above about 1.5 to 1.8 g/L in massively bleeding patients, while targeted fibrinogen replacement is recommended when a real deficit is present. [\[1\]](#cite-1 "Reference [1]") Fibrinogen replacement concept ------------------------------ Conceptually, fibrinogen replacement is not 'extra blood product'; it is early reconstruction of clot architecture. Recent trauma guidance recommends fibrinogen concentrate or cryoprecipitate when major bleeding is accompanied by viscoelastic evidence of functional fibrinogen deficiency or a Clauss fibrinogen of 1.5 g/L or lower, with an initial dose around 3 to 4 g or 15 to 20 single-donor units of cryoprecipitate. In cardiac surgical bleeding, recent guidance similarly advises considering fibrinogen substitution for persistent microvascular bleeding when fibrinogen is below 1.5 g/L, but not routine prophylactic fibrinogen for everyone. That board distinction matters: **targeted** replacement is defensible; blind, universal fibrinogen loading is not. [\[1\]](#cite-1 "Reference [1]") The product matters less than the principle. Cryoprecipitate brings fibrinogen plus factor XIII, factor VIII, and vWF; fibrinogen concentrate offers standardized dosing and faster preparation in many systems. In the FIBRES randomized trial, 4 g of fibrinogen concentrate was noninferior to 10 units of cryoprecipitate for hypofibrinogenemic bleeding after cardiac surgery. But do not overlearn that as 'give fibrinogen to all trauma patients early': CRYOSTAT-2 found no mortality benefit from adding early empirical high-dose cryoprecipitate to standard care in unselected bleeding trauma patients. Replace **documented or strongly suspected deficiency**, not anxiety. [\[3\]](#cite-3 "Reference [3]") Platelet thresholds concept --------------------------- Platelet transfusion is similar: think threshold plus phenotype. For trauma patients with ongoing bleeding, recent guidance suggests maintaining the platelet count above 50 × 10^9/L, and above 100 × 10^9/L when TBI is present. Cardiac surgery guidance still supports transfusing bleeding patients with platelet counts under 50 × 10^9/L, and it explicitly acknowledges that active bleeding on antiplatelet therapy may justify platelets even when the count is not profoundly low. The exam trap is assuming a normal platelet count means platelet hemostasis is adequate. It does not. After bypass or recent P2Y12 exposure, function may be the defect. [\[1\]](#cite-1 "Reference [1]") Clinical pictureMost useful clueFirst hemostatic moveWeak fibrin-based clotClauss fibrinogen ≤1.5 g/L or low FIBTEM/functional fibrinogenCryoprecipitate or fibrinogen concentrateThrombocytopenia/platelet dysfunctionPlatelets <50 × 10^9/L, or weak overall clot with preserved fibrin channelPlateletsMixed coagulopathyMultiple abnormalities plus ongoing diffuse bleedingBalanced transfusion, then repeat targeted testing Use the table as a bedside mental model, not a substitute for repeat reassessment. [\[1\]](#cite-1 "Reference [1]") Viscoelastic-guided therapy concept ----------------------------------- Viscoelastic testing earns its place because it answers a different question from PT/INR. Standard labs are often too slow in major hemorrhage, with reported turnaround times of roughly 27 to 77 minutes, and they are limited at predicting who will bleed. VHA gives a real-time description of clot initiation, strength, and lysis, which is exactly what the anesthesiologist needs when the field is filling now, not in 45 minutes. Trauma guidance recommends continuing resuscitation with a goal-directed strategy guided by standard labs and/or viscoelastic monitoring, rather than staying empirical once monitoring is available. [\[4\]](#cite-4 "Reference [4]") The high-yield interpretation is simple. If overall clot strength is low and the fibrinogen-specific channel is also low, think fibrinogen deficiency. If overall clot strength is low but the fibrinogen channel is preserved, think platelets. If clot initiation is prolonged after fibrinogen has been corrected, then think coagulation factor deficiency and only then escalate to plasma or PCC according to your algorithm. BSH guidance makes this distinction explicit, and trauma guidance recommends factor concentrates only when standard labs and/or viscoelastic testing show functional factor deficiency. That is the heart of coagulopathy-directed therapy: treat the failing part of clot mechanics, not the entire transfusion menu. [\[4\]](#cite-4 "Reference [4]") Do not oversell VHA. It is not magic, and preoperative screening value is limited. Its strength is serial intraoperative or resuscitation use inside a validated algorithm. In cardiac surgery, multiple meta-analyses summarized in the 2024 EACTS/EACTAIC guideline found lower transfusion requirements with TEG/ROTEM-guided algorithms and possible reductions in mortality and AKI. The practical lesson is not that every trace is perfect; it is that structured, repeated, point-of-care hemostatic decisions beat ad hoc product chasing. [\[5\]](#cite-5 "Reference [5]") Clinical correlations --------------------- In the OR, your leadership script should be deliberate: say, 'This is diffuse coagulopathic bleeding. Send repeat fibrinogen and VHA now. Give fibrinogen replacement first. Recheck clot strength in 10 minutes. Keep ionized calcium normal, warm the patient, and do not wait for the INR to normalize before acting.' That turns a chaotic MTP into directed resuscitation and scores points on oral boards because it shows mechanism, prioritization, and reassessment. [\[1\]](#cite-1 "Reference [1]") Key Takeaways ------------- - **Fibrinogen falls early** in major hemorrhage; replace it when bleeding is accompanied by fibrinogen ≤1.5 g/L or viscoelastic evidence of functional deficiency. [\[1\]](#cite-1 "Reference [1]") - **Do not use plasma as your main fibrinogen strategy** when the problem is hypofibrinogenemia. [\[1\]](#cite-1 "Reference [1]") - **Platelet targets are contextual:** aim above 50 × 10^9/L in ongoing bleeding and above 100 × 10^9/L with TBI; remember that dysfunction can exist with a normal count. [\[1\]](#cite-1 "Reference [1]") - **Viscoelastic testing is most useful for phenotype recognition** and serial reassessment after therapy. [\[4\]](#cite-4 "Reference [4]") - **Board pitfall:** treating the INR instead of the bleeding mechanism. Lead with clot mechanics. [\[4\]](#cite-4 "Reference [4]") Coagulopathy-directed therapy is not about giving more products; it is about giving the right product next. Think fibrinogen first, respect platelet thresholds without forgetting function, and use viscoelastic testing to turn 'oozing everywhere' into a treatable phenotype. [\[1\]](#cite-1 "Reference [1]") Frequently Asked Questions ---------------------------- ### When should fibrinogen be replaced during massive hemorrhage? Replace it when active bleeding is present with Clauss fibrinogen ≤1.5 g/L or viscoelastic evidence of functional fibrinogen deficiency; avoid routine empiric use in every bleeding patient. [\[1\]](#cite-1 "Reference [1]") ### Is cryoprecipitate better than fibrinogen concentrate? Both are acceptable targeted fibrinogen sources. Concentrate offers standardized rapid dosing, while cryoprecipitate adds other clot proteins; in cardiac surgery, 4 g concentrate was noninferior to 10 units cryoprecipitate. [\[3\]](#cite-3 "Reference [3]") ### What platelet count should trigger concern in active bleeding? A practical target is >50 × 10^9/L in ongoing bleeding and >100 × 10^9/L in TBI, but platelet dysfunction may justify treatment even when the count is higher. [\[1\]](#cite-1 "Reference [1]") ### How does viscoelastic testing help separate platelet and fibrinogen problems? Low overall clot strength with a low fibrinogen-specific channel suggests fibrinogen deficiency; low overall strength with a preserved fibrinogen channel points more toward a platelet problem. [\[4\]](#cite-4 "Reference [4]") ### Should I wait for viscoelastic results before treating severe hemorrhage? No. Start empiric hemorrhage resuscitation when the patient is exsanguinating, but once monitoring is available, shift quickly to goal-directed therapy rather than staying purely empirical. [\[1\]](#cite-1 "Reference [1]") References (8) ------------------ 1. 1. [ ccforum.biomedcentral.com/counter/pdf/10.1186/s13054-023-04327-7.pdf ](https://ccforum.biomedcentral.com/counter/pdf/10.1186/s13054-023-04327-7.pdf) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ ccforum.biomedcentral.com/articles/10.1186/s13054-019-2347-3 ](https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2347-3) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ Callum J, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. 2019. ](https://jamanetwork.com/journals/jama/fullarticle/2753529) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ Curry NS, et al. The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology. 2018. ](https://b-s-h.org.uk/media/16489/curry_et_al-2018-british_journal_of_haematology.pdf) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ Casselman FPA, et al. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP. ](https://academic.oup.com/ejcts/article/67/5/ezae352/7815985) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ Rossaint R, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Critical Care. 2023. ](https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04327-7) 7. 7. [ Kozek-Langenecker SA, et al. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care, second update 2022. ](https://pubmed.ncbi.nlm.nih.gov/36855941/) 8. 8. [ Curry N, et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA. 2023. ](https://jamanetwork.com/journals/jama/fullarticle/2810756) Next Build momentum in Anesthesiology with focused, exam‑style practice -------------------------------------------------------------------- - Airway, ventilation, and crisis drills - High‑yield anesthesia pharmacology made practical - Track weak topics and improve faster [ Start practicing ](https://mdster.com/user/dashboard) [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. Explore topics: [ # Anesthesiology ](https://mdster.com/blog?tag=anesthesiology) [ # Anesthesiology Boards ](https://mdster.com/blog?tag=anesthesiology-boards) [ # Transfusion Medicine ](https://mdster.com/blog?tag=transfusion-medicine) [ # Massive Hemorrhage ](https://mdster.com/blog?tag=massive-hemorrhage) [ # Coagulopathy ](https://mdster.com/blog?tag=coagulopathy) [ # Viscoelastic Testing ](https://mdster.com/blog?tag=viscoelastic-testing) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First 5 min read May 25, 2026 ](https://mdster.com/blog/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first) [### Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery 5 min read May 24, 2026 ](https://mdster.com/blog/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery) [### Inter-Rater Reliability and Kappa in Pediatrics: Board-Level Stats 5 min read May 23, 2026 ](https://mdster.com/blog/inter-rater-reliability-and-kappa-in-pediatrics-board-level-stats) Related Posts ------------- [ ![Liver Transplant Anesthesia: Reperfusion Collapse Case](https://mdster.com/storage/blog/images/liver-transplant-anesthesia-reperfusion-collapse-case.jpg) Case Discussion ### Liver Transplant Anesthesia: Reperfusion Collapse Case A board-focused liver transplant anesthesia case covering postreperfusion syndrome, hyperkalemia, citrate toxicity, fibrinolysis, and ICU handoff priorities. 6 min read 0 comments ](https://mdster.com/blog/liver-transplant-anesthesia-reperfusion-collapse-case) [ ![Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First](https://mdster.com/storage/blog/images/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first.jpg) Medical Education ### Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First Learn a high-yield, board-focused approach to type 2 diabetes pharmacotherapy using ASCVD, HF, CKD, adverse effects, and insulin triggers. 5 min read 0 comments ](https://mdster.com/blog/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first) [ ![Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery](https://mdster.com/storage/blog/images/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery.jpg) Medical Education ### Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery Recognize acute severe colitis and toxic megacolon early, use IV steroids correctly, and know when rescue therapy or colectomy is the safest move. 5 min read 0 comments ](https://mdster.com/blog/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery) [ ![Inter-Rater Reliability and Kappa in Pediatrics: Board-Level Stats](https://mdster.com/storage/blog/images/inter-rater-reliability-and-kappa-in-pediatrics-board-level-stats.jpg) Medical Education ### Inter-Rater Reliability and Kappa in Pediatrics: Board-Level Stats A focused pediatric board review of inter-rater reliability, Cohen’s kappa, prevalence limitations, and why agreement matters in clinical scoring. 5 min read 0 comments ](https://mdster.com/blog/inter-rater-reliability-and-kappa-in-pediatrics-board-level-stats) [ ![Multimodal Analgesia for Safer Postoperative Pain Plans](https://mdster.com/storage/blog/images/multimodal-analgesia-for-safer-postoperative-pain-plans.jpg) Medical Education ### Multimodal Analgesia for Safer Postoperative Pain Plans Learn how to build safer postoperative multimodal analgesia plans using acetaminophen, NSAIDs, regional anesthesia, opioids, gabapentinoids, ketamine, and lidocaine. 5 min read 0 comments ](https://mdster.com/blog/multimodal-analgesia-for-safer-postoperative-pain-plans) [ ![Serotonin Syndrome and NMS Treatment in Emergency Medicine](https://mdster.com/storage/blog/images/serotonin-syndrome-and-nms-treatment-in-emergency-medicine.jpg) Medical Education ### Serotonin Syndrome and NMS Treatment in Emergency Medicine Treat serotonin syndrome and NMS with the right ED priorities: stop offending agents, use benzodiazepines, cool early, and know cyproheptadine’s limits. 5 min read 0 comments ](https://mdster.com/blog/serotonin-syndrome-and-nms-treatment-in-emergency-medicine) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept